A rheumatologist ranks peptides she pitches for inflammation. These are her picks and claims, not established treatments.
Recap by typeshit. Full story at MYAutoimmuneMD .
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
A Cary-based company pulled its GLP-1 injections following attention from the FDA. The Business Journals has the details on the recall.
Amgen pointed to encouraging interim MariTide data and says the drug is moving quickly toward late-stage testing ahead of its Q3 earnings.
Loading…